Dealmakers' Intentions: 2019 Market Outlook

12:15 PM - 1:30 PM, Wednesday, June 5, 2019 ・ 113ABC, Level 100
After a multi-year expansion of company formation and in biopharma valuations, 2018 was a year of heightened market volatility. As interest rate worries, international trade disputes, and regulatory reimbursement uncertainty have increased, biopharma stock indexes have seen significant corrections. With historically high valuations experiencing sudden dips, M&A deal-making seems to have reignited with notable, multi-billion dollar deals in early 2019. A highly distinguished panel of deal-makers will explore the impact these market forces will have on pharmaceutical and biotech companies as they strive to make the next big deal. Session attendees will hear updated findings from two unique, forward-looking measures of deal-making in the industry the Syneos Health Dealmakers' Intentions Study and the BIO One-on-One Partnering Forecast. Based on a survey of more than 150 industry executives and business development professionals, Dealmakers' Intentions provides insight into what will likely drive the industry's partnering and M&A efforts moving forward and the implications for deal-making over the next year or more. Now in its 11th year, analysis will include year-over-year trends, deal metrics and broader M&A data. Sponsored by: Syneos Health
Senior Partner
Gurnet Point Capital
Vice President, Industry Research
Biotechnology Innovation Organization
Chief Business Officer
Boston Pharmaceuticals
Managing Director, Healthcare Investment Banking
Wells Fargo
Head, Transaction Excellence
Senior Director, Oncology Business Development
Eli Lilly and Company
Roivant Pharma